SCHEDULE 13G: LCK JNK 1 LLC Discloses 9.5% Stake in Scinai Immunotherapeutics Ltd.
Beneficial Ownership Report (Schedule 13G)
LCK JNK 1 LLC has filed a Schedule 13G, revealing a beneficial ownership of 9.5% of Scinai Immunotherapeutics Ltd.'s American Depositary Shares.
Summary
- LCK JNK 1 LLC, a U.S.-based entity, has filed a Schedule 13G with the SEC, indicating beneficial ownership in Scinai Immunotherapeutics Ltd.
- The filing reports that LCK JNK 1 LLC beneficially owns 80,757 American Depositary Shares (ADS) of Scinai Immunotherapeutics Ltd.
- Each American Depositary Share represents 4,000 Ordinary Shares, meaning LCK JNK 1 LLC's stake equates to 323,028,000 Ordinary Shares.
- This ownership represents 9.5% of the total class of securities, based on 3,411,983,584 ordinary shares outstanding as of September 30, 2024.
- Richard J. Kertzman is identified as the managing member of LCK JNK 1 LLC and may be deemed to indirectly beneficially own the securities.
- The filing certifies that the securities were not acquired for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While a 13G is a factual disclosure, the emergence of a new significant investor can be viewed as a positive signal of confidence in the company, although the filing itself contains no forward-looking statements or performance metrics.
Positives
- The disclosure of a significant stake by an investment entity like LCK JNK 1 LLC can signal investor confidence in Scinai Immunotherapeutics Ltd.'s future prospects.
- The filing is a routine regulatory disclosure, indicating transparency in ownership structure.
Risks
- The filing explicitly states that the securities were not acquired for the purpose of changing or influencing the control of the issuer, mitigating potential risks associated with activist investor intentions.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant ownership stake in a publicly traded company, common across all industries. It does not provide specific insights into broader industry trends for biotechnology or pharmaceuticals, but rather reflects an investment decision by a specific entity.
Stakeholder Impact
- Shareholders: The disclosure provides transparency regarding a significant ownership stake, which can influence market perception and potentially share price.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | Date as of which 3,411,983,584 ordinary shares were outstanding, as disclosed by the issuer. |
| 2024-11-22 | Date the issuer disclosed the number of ordinary shares outstanding. |
| 2025-02-09 | Date of event which required the filing of this statement (crossing the 5% beneficial ownership threshold). |
| 2025-02-24 | Date the Schedule 13G statement was signed and filed. |
Keywords
Scinai Immunotherapeutics Ltd., LCK JNK 1 LLC, Schedule 13G, Beneficial Ownership, American Depositary Shares, Ordinary Shares, SEC Filing, Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.